Navigation Links
Kite Pharma Appoints Cynthia M. Butitta as Chief Financial Officer

LOS ANGELES, Jan. 8, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT™) products for cancer, today announced the appointment of Cynthia M. Butitta to the newly created position of Executive Vice President and Chief Financial Officer.  A veteran financial and operational executive, Ms. Butitta brings over 20 years' experience in leadership roles in the biotech and technology industries.  Her appointment is effective immediately.


Arie Belldegrun, M.D., Founder and Executive Chairman of the Board of Kite Pharma, commented, "Cindy has an outstanding track record and depth and breadth of experience in capital fund raising, strategic planning and investor relations at both private and public biotechnology companies.  We are delighted to welcome her to the team and believe her unique capabilities and expertise will greatly benefit Kite as we pursue our clinical and business objectives."

Prior to joining Kite, Ms. Butitta served as Senior Vice President, Chief Financial Officer of NextWave Pharmaceuticals.  During her tenure, Ms. Butitta was responsible for finance and administration, distribution and project management and played a key role in the Company's acquisition by Pfizer, Inc. for $700 million.  Previously, she was Chief Financial Officer and Chief Operating Officer of Telik, Inc.  At Telik, Ms. Butitta was responsible for securing over $450 million through an IPO and subsequent follow-on offerings and oversaw financial reporting and controls, investor relations, information technology, manufacturing, quality, project management and commercial operations.  Previously, she served as Vice President of Finance and Administration and Chief Financial Officer for Connetics, Inc., a public biotechnology company.  Ms. Butitta received her B.S. degree with honors in Business and Accounting from Edgewood College in Madison, Wisconsin and her MBA degree in Finance from the University of Wisconsin, Madison.

Ms. Butitta stated, "I am thrilled to join the accomplished executive management team at Kite.  As a leading company in the emerging and highly promising field of immunotherapy, Kite has the opportunity to play a pivotal role in changing the way we approach cancer.  It is an exciting time for the Company, with recent clinical breakthroughs reported at a major cancer conference, and I look forward to contributing to Kite's continued evolution and growing presence within the life sciences industry."

About Kite Pharma

Kite Pharma, Inc. (Kite) is a privately held development stage biotechnology company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch, Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR and TCR products, directed to a wide range of cancer indications. These novel personalized and targeted immunotherapies, which capitalize on the selectivity and potency of immune cells, are designed to provide significant and durable clinical benefit regardless of tumor origin, disease stage, and prior treatments. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing cutting-edge immunotherapies and oncology treatments. Kite is based in Los Angeles, CA.  For more information, visit the company's website at

Kite Contact:
Dr. Arie Belldegrun
Executive Chairman

For Media:
Justin Jackson
Burns McClellan
(212) 213-0006

SOURCE Kite Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Upcoming Conferences, Share Price Updates, and Leadership Changes - Research Report on Lilly, Allergan, Waters, Novavax, and Supernus Pharmaceuticals
2. Auxilium Pharmaceuticals, Inc. To Present At The J.P. Morgan 32nd Annual Healthcare Conference
3. Questcor Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
4. Sutro Biopharma to Collaborate With Memorial Sloan-Kettering Cancer Center to Produce Bispecific Antibodies for the Treatment of Neuroblastoma
5. Kite Pharma to Present at the 32nd Annual J.P. Morgan Healthcare Conference
6. Study Updates, Notices, Quarterly Reports, and Revenue Guidance Updates - Research Report on NPS Pharmaceuticals, Oramed, PAREXEL, PhotoMedex, and Cell Therapeutics
7. Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
8. Velocity Pharmaceutical Development Announces Appointment of Stuart Sedlack as Senior Vice President, Business Development
9. Jazz Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 13
10. Ralphs Pharmacies Providing Prescriptions at No Upfront Cost for Customers Enrolled in the Public Health Insurance Marketplace
11. CVS/pharmacy Helps Customers Kick Off a Healthy New Year with Online Vitamin Resources and Huge Savings
Post Your Comments:
(Date:10/13/2015)... 13, 2015 According to the ... sponsored by Cardinal Health , achieving both ... diversified pharmacy revenue streams are vital to the ... NCPA Digest affirms that independent community ... in underserved inner city and rural areas," said ...
(Date:10/13/2015)... -- Measurement in accountable care programs is essential for ... gaps in measurement can result in missed opportunities ... new, peer-reviewed study published in The ... measurement gaps for high-priority conditions and identifies ways ... --> "These gaps in measures present ...
(Date:10/13/2015)... DUBLIN , Oct. 13 2015 ... addition of the "US & European markets ... report to their offering. --> ... "US & European markets for Meniscal Repair - ... --> Research and Markets ( ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... According to an article ... has shown that women who successfully lose weight with a bariatric procedure are much ... each year. The article notes that anywhere from 40 to 50 percent of all ...
(Date:10/13/2015)... , ... October 13, 2015 , ... In an age ... costs were 36 percent lower per square foot than in 2009. The Williamsport Regional ... of heating and cooling has decreased by eight percent. , According to Facilities ...
(Date:10/13/2015)... ... October 13, 2015 , ... A child without a healthy mouth is ... the leading remote invisible aligner system, has joined with Global Dental Relief ... For each aligner treatment plan purchased, SmileCareClub will donate one clinic visit to a ...
(Date:10/13/2015)... ... , ... Scientists in Seattle and Vancouver compared the diagnostic value of lung ... Surviving Mesothelioma has just posted an article on the new research. Click here ... the University of British Columbia found that certain genetic alterations were seen just as ...
(Date:10/13/2015)... , ... October 13, 2015 , ... World Patent ... Snow Blanket, a snow melting invention that helps people in clearing snow away from ... will continue to grow at 3.8% per year," says Scott Cooper, CEO and Creative ...
Breaking Medicine News(10 mins):